Porton Pharma Solutions Ltd. (300363.SZ) Bundle
Dive into Porton Pharma Solutions Ltd.'s financial snapshot: Q3 2025 revenue jumped to 923.49 million CNY (+19.44% QoQ) while trailing twelve-month revenue hit 3.43 billion CNY (+24.51% YoY) against a 2024 full-year decline to 3.01 billion CNY (-17.87%); Q3 net profit attributable rose to 79.92 million CNY (+138.71% YoY) even as the company posted a 287.8 million CNY net loss in 2024 and a TTM net loss of 1.41 million CNY; balance-sheet metrics show net debt of 66.4 million CNY with cash of 1.44 billion CNY and total debt of 1.37 billion CNY, a conservative debt-to-equity of 0.31, enterprise value of 14.18 billion CNY (EV/Revenue 4.13; EV/EBITDA 27.39) and interest coverage of 1.70; liquidity is solid (current ratio 1.87, quick ratio 1.38) but returns lag (ROE -1.35%, ROA 0.71%), valuation multiples sit at trailing P/E 10.42, forward P/E 41.90, P/S 3.97 and P/B 2.48 while P/FCF stretches to 79.04, and growth prospects include over 2,200 projects with ~800 global customers, strategic partnerships, and analyst forecasts of earnings and revenue growth of 96.4% and 12.3% p.a. respectively (EPS growth 95.6% p.a.; ROE projected 7.1% in three years), setting the stage for a deeper look at what these figures mean for investors.
Porton Pharma Solutions Ltd. (300363.SZ) - Revenue Analysis
Porton Pharma's recent top-line performance shows a mix of strong recovery in multi-year trailing figures and volatility year-to-year. Key headline numbers provide context for operational scale and recent momentum.
- Q3 2025 revenue: 923.49 million CNY (up 19.44% quarter-over-quarter).
- Trailing twelve months (TTM) revenue: 3.43 billion CNY (up 24.51% year-over-year).
- 2024 annual revenue: 3.01 billion CNY (down 17.87% vs. 2023).
- 2023 annual revenue: 3.67 billion CNY (down 47.87% vs. 2022).
- 2022 annual revenue: 7.00 billion CNY (up 127% vs. 2021).
- Revenue per employee: ~814,227 CNY, based on 4,214 employees.
| Period | Revenue (CNY) | Reported Change | Notes |
|---|---|---|---|
| Q3 2025 (quarter) | 923,490,000 | +19.44% QoQ | Strong sequential recovery |
| TTM (to Q3 2025) | 3,430,000,000 | +24.51% YoY | Improving annualized run-rate |
| 2024 (annual) | 3,010,000,000 | -17.87% YoY | Decline vs. 2023 |
| 2023 (annual) | 3,670,000,000 | -47.87% YoY | Sharp drop vs. 2022 |
| 2022 (annual) | 7,000,000,000 | +127.00% YoY | Significant growth vs. 2021 |
| Employees | 4,214 | - | Revenue per employee ≈ 814,227 CNY |
- Volatility analysis: The swing from 7.00B CNY in 2022 to 3.67B in 2023 and 3.01B in 2024 highlights material year-to-year variability; however, TTM growth of 24.51% and a QoQ rebound in Q3 2025 suggest recovery dynamics.
- Operational efficiency: Revenue per employee (~814k CNY) indicates moderate per-capita productivity for a pharma services firm of this scale; useful for benchmarking against peers.
- Investor focus areas: monitor whether Q3 2025 quarter-over-quarter strength sustains into subsequent quarters to confirm the TTM growth trajectory.
Further context on strategic positioning and long-term objectives is available here: Mission Statement, Vision, & Core Values (2026) of Porton Pharma Solutions Ltd.
Porton Pharma Solutions Ltd. (300363.SZ) - Profitability Metrics
Recent quarterly and annual results show a pronounced turnaround in quarterly profitability after a loss-making 2024. Key headline figures for Q3 2025 and recent trailing metrics:
- Q3 2025 net profit attributable to shareholders: 79.92 million CNY (YoY +138.71%).
- Q3 2025 net profit after deducting non-recurring items: 53.68 million CNY (YoY +125.14%).
- Q3 2025 basic EPS: 0.15 CNY.
- Full year 2024 net result: net loss of 287.8 million CNY, versus a profit of 266.9 million CNY in 2023 (a 208% decline).
- Trailing twelve months (TTM) net income: loss of 1.41 million CNY.
- TTM EPS: -0.00 CNY (loss per share).
| Period | Metric | Value (CNY) | YoY/Notes |
|---|---|---|---|
| Q3 2025 | Net profit attributable to shareholders | 79.92 million | +138.71% YoY |
| Q3 2025 | Net profit (after non-recurring items) | 53.68 million | +125.14% YoY |
| Q3 2025 | Basic EPS | 0.15 | - |
| Full year 2024 | Net profit / (loss) | (287.8) million | Decline vs 2023 profit of 266.9 million (208% swing) |
| TTM | Net income | (1.41) million | Loss over trailing 12 months |
| TTM | EPS | -0.00 | Loss per share |
Key implications for investors:
- The sharp QoQ/Yoy improvement in Q3 2025 indicates operational recovery or one-off favorable items driving quarterly profitability.
- The wide gap between quarterly profit and TTM/annual results highlights volatility-2024's substantial loss offsets recent quarterly gains on a TTM basis.
- Investors should monitor whether Q3 trends persist into subsequent quarters to restore multi-quarter positive TTM earnings and EPS.
Further reading: Exploring Porton Pharma Solutions Ltd. Investor Profile: Who's Buying and Why?
Porton Pharma Solutions Ltd. (300363.SZ) - Debt vs. Equity Structure
Key balance-sheet and valuation metrics as of March 2025 show Porton Pharma Solutions Ltd. maintaining a conservative leverage profile while trading at elevated valuation multiples relative to earnings.
- Net debt: 66.4 million CNY (total debt 1.37 billion CNY less cash 1.44 billion CNY)
- Debt-to-equity ratio: 0.31 - indicates modest reliance on debt financing
- Enterprise value (EV): 14.18 billion CNY; Market capitalization: 13.63 billion CNY
- EV / Revenue: 4.13
- EV / EBITDA: 27.39
- Interest coverage ratio: 1.70
| Metric | Value | Notes |
|---|---|---|
| Total debt | 1,370,000,000 CNY | Includes short- and long-term borrowings |
| Cash & equivalents | 1,440,000,000 CNY | Liquidity cushion exceeds gross debt |
| Net debt | 66,400,000 CNY | Net position close to neutral |
| Debt-to-equity ratio | 0.31 | Conservative leverage |
| Market capitalization | 13,630,000,000 CNY | Equity market value |
| Enterprise value (EV) | 14,180,000,000 CNY | EV = Market cap + Net debt (approx.) |
| EV / Revenue | 4.13 | Valuation relative to top line |
| EV / EBITDA | 27.39 | High multiple vs. earnings |
| Interest coverage ratio | 1.70 | Ability to service interest is moderate |
Implications for investors:
- Strong cash holdings relative to gross debt create flexibility for R&D and capital allocation.
- Low debt-to-equity suggests limited financial risk from leverage but EV/EBITDA near 27.4 signals high expectations priced into the stock.
- Interest coverage of 1.70 means earnings cushion for interest is modest; monitoring EBITDA trend is important.
For broader context on company objectives and strategic direction, see Mission Statement, Vision, & Core Values (2026) of Porton Pharma Solutions Ltd.
Porton Pharma Solutions Ltd. (300363.SZ) Liquidity and Solvency
Porton Pharma Solutions Ltd. presents a mixed liquidity and solvency profile: short-term coverage appears comfortable, while profitability and returns on capital show limited strength. Key ratios (most recent reported) are summarized below.
| Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.87 | Sufficient short-term assets to cover short-term liabilities |
| Quick Ratio | 1.38 | Adequate liquidity without relying on inventory |
| Return on Equity (ROE) | -1.35% | Negative return on shareholders' equity |
| Return on Assets (ROA) | 0.71% | Low efficiency in converting assets to profit |
| Return on Invested Capital (ROIC) | 0.84% | Modest returns from capital investments |
| Return on Capital Employed (ROCE) | 1.43% | Limited efficiency generating profit from capital employed |
- Strong short-term liquidity: current ratio of 1.87 and quick ratio of 1.38 reduce short-term solvency risk.
- Negative ROE (-1.35%) indicates shareholder equity is not generating positive returns - potential concern for equity investors.
- Low ROA (0.71%), ROIC (0.84%), and ROCE (1.43%) suggest constrained profitability relative to assets and capital deployed.
- Liquidity cushions provide time for operational improvements or strategic investments to enhance returns.
For additional context on the company's broader background and business model, see: Porton Pharma Solutions Ltd.: History, Ownership, Mission, How It Works & Makes Money
Porton Pharma Solutions Ltd. (300363.SZ) Valuation Analysis
Porton Pharma Solutions Ltd. (300363.SZ) presents a mixed valuation profile: relatively low trailing earnings multiple alongside a much higher forward P/E and elevated cash-flow and sales multiples, implying market expectations for future earnings growth but limited current free-cash-flow coverage.- Trailing P/E: 10.42 - current earnings multiple.
- Forward P/E: 41.90 - market-priced expected earnings growth.
- P/S (Price-to-Sales): 3.97 - price relative to revenue scale.
- P/B (Price-to-Book): 2.48 - price relative to accounting book value.
- P/TBV (Price-to-Tangible Book): 2.84 - price relative to tangible equity.
- P/FCF (Price-to-Free Cash Flow): 79.04 - high premium to free cash flow.
| Metric | Value | Interpretation |
|---|---|---|
| Trailing P/E | 10.42 | Historically modest earnings multiple; may signal value or cyclical earnings. |
| Forward P/E | 41.90 | Market expects significant EPS growth; implies higher future performance required to justify price. |
| P/S | 3.97 | Investors pay ~4x annual revenue; moderate revenue multiple for pharma/services. |
| P/B | 2.48 | Price > book value; reflects intangible assets, growth expectations. |
| P/TBV | 2.84 | Tangible assets cover a smaller portion of market cap; premium for intangibles/operations. |
| P/FCF | 79.04 | Very high - limited free cash flow relative to market cap; signals liquidity or reinvestment dynamics. |
- The gap between trailing (10.42) and forward P/E (41.90) indicates the market is pricing in material EPS improvement.
- High P/FCF (79.04) raises sensitivity to cash-flow volatility; small changes in FCF could materially affect valuation.
- P/S of 3.97 and P/B of 2.48 show investors attribute growth and intangible value beyond accounting book equity.
- Relative attractiveness depends on conviction in earnings recovery/growth and cash-generation improvements.
Porton Pharma Solutions Ltd. (300363.SZ) Risk Factors
Porton Pharma Solutions Ltd. operates in the highly competitive global contract development and manufacturing organization (CDMO) market, where pricing pressure, capacity competition and technological differentiation materially affect margins and growth prospects.- 2024 performance shock: reported net loss of -287.8 million CNY, a 208% decline from the prior year's profit (implied 2023 net income ≈ +266.5 million CNY).
- Near-breakeven TTM performance: trailing twelve months (TTM) net income stands at a loss of -1.41 million CNY, indicating recent stabilization but continued vulnerability to setbacks.
- Negative shareholder returns: return on equity (ROE) of -1.35% signals a negative return on shareholders' capital.
- Limited asset efficiency: return on assets (ROA) of 0.71%-low but positive-shows modest profit generation from its asset base.
- Modest capital returns: return on invested capital (ROIC) of 0.84% suggests limited ability to generate strong returns from deployed capital.
- Operational and execution risks: ramping production, ensuring regulatory compliance, and converting pipeline contracts to profitable volumes are material operational hazards.
- Customer concentration and contract risk: dependence on a limited number of large CDMO contracts can amplify revenue volatility if renewals or volumes change.
- Macro and funding risks: cyclical demand in pharma outsourcing, currency exposure, and the need for capital to fund capacity or R&D expansion may pressure liquidity and leverage.
| Metric | 2023 (Implied) | 2024 (Reported) | TTM |
|---|---|---|---|
| Net Income (CNY) | +266,480,000 | -287,800,000 | -1,410,000 |
| Change vs Prior Year | - | -208% (profit → loss) | - |
| Return on Equity (ROE) | - | -1.35% | -1.35% |
| Return on Assets (ROA) | - | 0.71% | 0.71% |
| Return on Invested Capital (ROIC) | - | 0.84% | 0.84% |
- Investor considerations: volatility stemming from the 2024 loss, marginal TTM profitability, and weak ROE argue for careful scrutiny of contract pipeline, margin recovery plans, and cash/financing runway.
- Monitor: contract mix, backlog convertibility, margin trends, capital expenditure plans, and any guidance revisions or restructuring actions by management.
Porton Pharma Solutions Ltd. (300363.SZ) - Growth Opportunities
Porton Pharma Solutions Ltd. (300363.SZ) exhibits several clear growth vectors driven by an extensive project backlog, strategic partnerships, forecasted rapid earnings expansion, and sustained capital investment.- Track record: >2,200 projects completed, serving ~800 global customers - a broad client base that supports recurring revenue and cross-selling opportunities.
- Strategic collaborations: active alliances with Aojin Life Sciences and Dragon Sail Pharmaceutical to advance drug development and manufacturing scale-up.
- Capital investment: planned capital expenditures of CNY 1.4-1.7 billion in 2023 to expand capacities and support new service lines.
| Metric | Current / Baseline | 3-Year Projection | Annualized Growth |
|---|---|---|---|
| Revenue (annual) | - | - | 12.3% p.a. (next 3 years) |
| Earnings (net profit) | - | - | 96.4% p.a. (next 3 years) |
| EPS | - | - | 95.6% p.a. (forecast) |
| Return on Equity (ROE) | - | 7.1% (in 3 years) | - |
| Capital Expenditures (2023) | - | CNY 1.4-1.7bn | - |
| Projects completed | >2,200 | - | - |
| Global customers | ~800 | - | - |
- Pipeline leverage: the large project count and customer base enable scale economies for both R&D services and contract manufacturing, accelerating margin expansion as revenue grows.
- Partnership-enabled acceleration: collaborations with Aojin Life Sciences and Dragon Sail Pharmaceutical create near-term product development milestones and potential co-commercialization pathways.
- CapEx-funded capacity: CNY 1.4-1.7bn in capex for 2023 positions Porton to capture higher-volume, higher-margin contracts and shorten lead times for clients.
Porton Pharma Solutions Ltd. (300363.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.